Olmutinib | Interleukin Related interleukin-related.com

Product Name :
Olmutinib

Search keywords :
Olmutinib

drugId :
null

Target Vo:
EGFR T790M

Target Vo Short Name :
EGFR T790M

Moa_Name:
EGFR T790M inhibitors

First Approval Country :
South Korea

First Approval Date Filter:
2016

Origin Company_Name :
Hanmi Pharmaceutical Co Ltd

Active Company_Name :
Hanmi Pharmaceutical Co Ltd

Active Indication_Name:
Carcinoma, Non-Small-Cell Lung

In Active Indication_Name:

Termination Status :

China Termination Status :
IND

Highest Status:
Approved

China Highest Status:
Discontinued

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Fulranumab Autophagy
Phospho-Nrf2(S40)Rabbit mAb manufacturer
eIF1A Antibody: eIF1A Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 16 kDa, targeting to eIF1A. It can be used for WB,IHC-F,IHC-P,ICC/IF,IP assays with tag free, in the background of Human, Mouse, Rat.

Author: Interleukin Related

Related Posts